When will the FDA approve Intellia Therapeutics' lonvo-z?

Prediction market on kalshi. If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.

24h Volume: $70.14. Liquidity: $125.2. Resolves: 10/8/2027.